Long-Course Chemoradiotherapy Preferred TNT Regimen for Rectal Cancer
By Elana Gotkine HealthDay Reporter
THURSDAY, Sept. 12, 2024 -- For patients with locally advanced rectal cancer pursuing organ preservation, long-course chemoradiotherapy (LCCRT) is the preferred total neoadjuvant therapy (TNT) regimen, according to a study published online Sept. 11 in the Annals of Oncology to coincide with the European Society for Medical Oncology Congress 2024, being held from Sept. 13 to 17 in Barcelona, Spain.
Aron Bercz, M.D., from Memorial Sloan Kettering Cancer Center in New York City, and colleagues examined potential differences in organ preservation in rectal cancer between TNT regimens integrating LCCRT and short-course radiotherapy (SCRT), the latter of which was introduced in response to the COVID-19 pandemic. The analyses included 323 locally advanced rectal adenocarcinoma patients treated with LCCRT (247 patients) and SCRT (76 patients) from January 2018 to January 2021. Organ preservation with watch-and-wait (WW) management was offered to patients who achieved clinical complete response.
Patients were followed for a median of 31 months. The researchers found similar clinical complete response rates after LCCRT and SCRT (44.5 versus 43.4 percent). Among patients treated with LCCRT and SCRT, two-year organ preservation was 40 and 31 percent, respectively. In patients managed with WW, compared with SCRT, LCCRT resulted in higher two-year organ preservation (89 versus 70 percent) and lower two-year local regrowth (19 versus 36 percent). WW patients treated with LCCRT and SCRT had similar two-year distant recurrence (10 versus 6 percent), disease-free survival (90 versus 90 percent), and overall survival (99 versus 100 percent).
"These findings provide timely insights for patients considering organ preservation strategies and support induction LCCRT followed by consolidation chemotherapy as the preferred TNT regimen," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
One-Week Radiotherapy for Breast Cancer Safe, Effective Up to 10 Years
TUESDAY, May 27, 2025 -- A five-fraction, one-week schedule of adjuvant breast radiotherapy is as safe and effective as a standard three-week schedule for patients with invasive...
Stereotactic Body Radiotherapy Feasible After Radical Prostatectomy
TUESDAY, May 20, 2025 -- Post-radical prostatectomy (post-RP) stereotactic body radiotherapy (SBRT) is well tolerated, with patient-reported outcomes (PROs) comparable to those...
Multitarget Stool DNA Tests More Costly Than FIT for Colorectal Cancer Detection
WEDNESDAY, May 14, 2025 -- Multitarget stool DNA test (MSDT)- and next-generation MSDT (N-G MSDT)-based screening have higher costs per detected advanced neoplasia case or early...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.